Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register
- 29 April 2018
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 181 (5), 614-627
- https://doi.org/10.1111/bjh.15243
Abstract
The myelodysplastic syndromes (MDS) have highly variable outcomes and prognostic scoring systems are important tools for risk assessment and to guide therapeutic decisions. However, few population‐based studies have compared the value of the different scoring systems. With data from the nationwide Swedish population‐based MDS register we validated the International Prognostic Scoring System (IPSS), revised IPSS (IPSS‐R) and the World Health Organization (WHO) Classification‐based Prognostic Scoring System (WPSS). We also present population‐based data on incidence, clinical characteristics including detailed cytogenetics and outcome from the register. The study encompassed 1329 patients reported to the register between 2009 and 2013, 14% of these had therapy‐related MDS (t‐MDS). Based on the MDS register, the yearly crude incidence of MDS in Sweden was 2·9 per 100 000 inhabitants. IPSS‐R had a significantly better prognostic power than IPSS (P < 0·001). There was a trend for better prognostic power of IPSS‐R compared to WPSS (P = 0·05) and for WPSS compared to IPSS (P = 0·07). IPSS‐R was superior to both IPSS and WPSS for patients aged ≤70 years. Patients with t‐MDS had a worse outcome compared to de novo MDS (d‐MDS), however, the validity of the prognostic scoring systems was comparable for d‐MDS and t‐MDS. In conclusion, population‐based studies are important to validate prognostic scores in a ‘real‐world’ setting. In our nationwide cohort, the IPSS‐R showed the best predictive power.Keywords
This publication has 40 references indexed in Scilit:
- Myelodysplastic syndrome in New Zealand and AustraliaInternal Medicine Journal, 2012
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registriesBlood, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesThe New England Journal of Medicine, 2011
- Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Haematologica, 2011
- Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsBlood, 2008
- Time-Dependent Prognostic Scoring System for Myelodysplastic Syndromes Has Significant Limitations That May Influence Its Reproducibility and Practical ApplicationJournal of Clinical Oncology, 2008
- New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsBlood, 2007
- Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic SyndromesJournal of Clinical Oncology, 2007
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994